Lineage Cell Therapeutics Inc
Research Lineage Cell Therapeutics Inc (LCTX) on Bullrun: market cap USD 285.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLCTX
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 285.79M
- Financial periodQ2 2026
- RevenueUSD 1.07M
- Net incomeUSD 1.48M
- Free cash flow-USD 7.35M
- Gross margin100.0%
Valuation Snapshot
latest market cap is USD 285.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 14.56M | -USD 63.53M | -USD 19.44M | 99.0% | -0.28 | USD 40.79M | USD 2.42M | USD 44.55M |
| FY2024 | USD 9.50M | -USD 18.61M | -USD 23.66M | 96.5% | -0.09 | USD 45.79M | USD 2.51M | USD 78.38M |
| FY2023 | USD 8.95M | -USD 21.49M | -USD 29.24M | 92.5% | -0.12 | USD 35.44M | USD 2.95M | USD 63.42M |
| FY2022 | USD 14.70M | -USD 26.27M | USD 646.00K | 95.0% | -0.15 | USD 11.36M | USD 2.10M | USD 73.34M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 285.79M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 406.01M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 110.21M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 190.74M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 198.87M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 415.22M | n/a | n/a | n/a |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lineage Cell Therapeutics Inc's market cap?
Lineage Cell Therapeutics Inc's market capitalization is USD 285.79M.
What does Lineage Cell Therapeutics Inc do?
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.